2020
DOI: 10.3892/mco.2020.2006
|View full text |Cite
|
Sign up to set email alerts
|

Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia

Abstract: Acute myeloid leukemia (AML) is a hematological malignancy with a poorly understood pathogenesis, especially among patients with no known cytogenetic abnormalities. Furthermore, there is a lack of therapeutic gene targets and diagnostic biomarkers for the effective treatment of AML. The present study aimed to identify candidate biomarkers correlated with the clinical prognosis of patients with AML. Leukemic cells from 5 patients with AML exhibiting a normal karyotype, and hematopoietic cells from 5 healthy don… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 33 publications
(34 reference statements)
0
3
0
Order By: Relevance
“…This hypothesis has been experimentally substantiated in various types of cancers, including hematological malignancies [40][41][42][43][44]. Nowadays, there are more and more studies involving applying WGCNA in AML-related analysis published in journals of different levels [45][46][47][48][49][50], which proves the recognition of this algorithm to some extent. However, there is no study aimed at finding AML survival-specific biomarkers using the WGCNA methodology based on adult CN-AML data by far.…”
mentioning
confidence: 74%
“…This hypothesis has been experimentally substantiated in various types of cancers, including hematological malignancies [40][41][42][43][44]. Nowadays, there are more and more studies involving applying WGCNA in AML-related analysis published in journals of different levels [45][46][47][48][49][50], which proves the recognition of this algorithm to some extent. However, there is no study aimed at finding AML survival-specific biomarkers using the WGCNA methodology based on adult CN-AML data by far.…”
mentioning
confidence: 74%
“…At Definition II for csPC (Gleason score ≥ 3 + 4 and/or MCCL ≥ 4 mm), both PSA density and LMTK2 were significant prebiopsy determinants for cancer risk stratification, thus indicating that LMTK2 expression is altered at early stages of cancer progression. Despite the fact that LMTK2 expression is not specific for prostate cancer [ 37 39 ] due to revealed interplay between LMTK2 and myosin IV—a regulator of PSA—it is widely investigated in prostate cancer [ 40 ]. LMTK2 also interacts with other proteins, such as protein phosphatase-1 (PP1C) and inhibitor-2 (Inh2), which are involved in cell division and the cyclin-dependent kinase 5 (cdk5)/ p 35 complex, which plays important role in cell cycle progression.…”
Section: Resultsmentioning
confidence: 99%
“…Gene expression profiling of AML patients has catalyzed the discovery of novel leukemia subgroups and of prognostic signatures [6]. The increasing availability of high-throughput data from blood and bone marrow of AML patients creates unprecedented opportunities for the comprehensive identification of diagnostic biomarkers of AML which could complement and update the existing ones [15][16][17]. Moreover, despite the poor outcomes of AML, there are a few fortunate cases that manage to survive over exceptionally extended periods of time, perhaps reflecting a remarkable resistance to MRD and disease progression.…”
Section: Introductionmentioning
confidence: 99%